Home > Canada Communicable Disease Report (CCDR) > Canada Communicable Disease Report 2013: Volume 39 > Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13)

Text Equivalent

Figure 1: Reported number of cases and incidence rate of invasive pneumococcal disease, Canada, 2001–2011

FIGURE 1. Reported number of cases and incidence rate of invasive pneumococcal disease, Canada, 2001–2011
Year Number of reported cases Incidence rate (per 100,000 population)
2001 1728 5.57
2002 2251 7.18
2003 2725 8.61
2004 2910 9.11
2005 2850 8.84
2006 2875 8.83
2007 3235 9.82
2008 3186 9.56
2009Footnote † 3311 9.82
2010Footnote † 3309 9.70
2011Footnote † 3274 9.49

Footnote * Data obtained from the Canadian Notifiable Disease Surveillance System.

Footnote † Based on preliminary data

Return to Figure 1

Figure 2: Mean number of cases and mean incidence rate of invasive pneumococcal disease (per 100,000 population), by province and territory, Canada, 2007–2011

FIGURE 2. Mean number of cases and mean incidence rate of invasive pneumococcal disease (per 100,000 population), by province and territory, Canada, 2007–2011
Province / Territory Mean Number of Cases Mean Incidence rate (per 100,000 population)
BC 373 8.37
AB 425 11.62
SK 131 12.69
MB 138 11.27
ON 1130 8.64
QC 926 11.83
NL 25 4.88
NB 68 9.04
NS 29 3.10
PE 0 0.00
YT 4 10.68
NT 10 21.98
NU 6 18.60

Return to Figure 2

FIGURE 3. Mean annual incidence of invasive pneumococcal disease by province and territory – all age groups (per 100,000 population), pre and post PNEU-C-7 implementation, Canada, 2001–2011

FIGURE 3. Mean annual incidence of invasive pneumococcal disease by province and territory – all age groups (per 100,000 population), pre and post PNEU-C-7 implementation, Canada, 2001–2011
Province / Territory Year PCV7 Implemented Mean annual incidence (per 100,000 population)
pre-PCV7 implementation		 Mean annual incidence (per 100,000 population)
post-PCV7 implementation
BC 2003 6.90 8.48
AB 2002 12.23 12.05
SK 2005 6.84 12.49
MB 2004 7.32 10.70
ON 2005 5.87 8.43
QC 2004 11.79 11.22
NL 2005 4.64 4.78
NB 2005 2.67 8.08
NS 2005 1.28 2.99
PE 2005 0.00 0.12
YT 2005 10.27 12.97
NT 2006 10.62 21.98
NU 2002 17.77 16.66

Footnote *Data obtained from the Canadian Notifiable Disease Surveillance System (Preliminary data from 2009–2011)

Footnote ** The year in which the program was initiated is included in pre-implementation. Data were available from 2001 to 2011 for all Provinces /Territories.

Return to Figure 3

FIGURE 4. Incidence rate of invasive pneumococcal disease in < 20 years old, by age group and year, Canada, 2001–2011

FIGURE 4. Incidence rate of invasive pneumococcal disease in < 20 years old, by age group and year, Canada, 2001–2011
Year <1 yrs 1 to 4 yrs 5 to 9 yrs 10 to 14 yrs 15 to 19 yrs
2001 37.37 25.17 3.57 1.15 1.42
2002 50.00 33.24 3.12 1.56 1.18
2003 54.51 35.55 4.36 1.17 0.99
2004 42.90 31.04 4.20 1.17 1.31
2005 25.06 21.60 5.20 1.79 1.29
2006 19.99 13.58 4.44 1.81 1.81
2007 30.54 15.75 3.44 1.95 2.14
2008 30.56 16.56 4.52 1.44 1.33
2009Footnote † 28.16 18.51 5.78 1.57 1.82
2010Footnote † 24.03 16.10 4.60 1.86 1.30
2011Footnote † 20.26 15.17 5.26 2.42 1.64

Footnote *Data obtained from the Canadian Notifiable Disease Surveillance System

Footnote † Based on preliminary data

Note: PNEU-C-7 was implemented in AB and NU in 2002, BC in 2003, MB and QC in 2004, SK, ON, NB, NS, PE, NL and YT in 2005, and NT in 2006.  PNEU-C-10 was introduced in some Canadian provinces and territories in 2009. The PNEU-C-13 vaccine was introduced in 2010.

Return to Figure 4

FIGURE 5. Incidence rate of IPD cases aged 20 years and older, by age group and year, Canada, 2001–2011

FIGURE 5. Incidence rate of IPD cases aged 20 years and older, by age group and year, Canada, 2001–2011
Year 20 to 24 yrs 25 to 29 yrs 30 to 39 yrs 40 to 59 yrs 60+ yrs
2001 1.57 1.88 2.54 4.08 10.71
2002 1.59 2.02 3.45 4.66 15.53
2003 1.38 3.00 4.74 6.49 18.33
2004 1.63 2.83 5.00 7.50 20.70
2005 2.60 3.21 4.92 8.08 20.36
2006 1.95 3.75 6.74 9.00 19.11
2007 3.30 4.44 7.09 10.16 20.37
2008 2.67 3.45 5.17 9.58 21.43
2009Footnote † 2.33 3.32 5.53 8.92 22.43
2010Footnote † 1.78 3.05 5.11 8.89 23.15
2011Footnote † 1.33 3.06 5.30 9.06 21.55

Footnote *Data obtained from the Canadian Notifiable Disease Surveillance System

Footnote † Based on preliminary data

Note: PNEU-C-7 introduction occurred in all provinces and territories by 2006.  PNEU-C-10 was introduced in some Canadian provinces and territories in 2009. PNEU-C-13 introduction occurred in 2010.

Return to Figure 5

Figure 6. Regional distribution of S. pneumoniae serotypes in Canada, 2011

This image is a stacked bar graph that describes the number of reported cases of invasive pneumococcal disease (IPD), by serotype and province or territory, in Canada during 2011.  The highest number of cases were reported by Ontario (n=1148), Quebec (n=434), Alberta (n=354) and British Columbia (n=318).  Serotype 19A had the highest number of reported cases (n= 436), followed by serotype 7F (n=407), 3 (n=232) and 22F (n=210). 

Among these predominant serotypes, only serotype 22F is not preventable by the PCV13 vaccine.  However, the Pneu-P-23 vaccine, which is currently licensed in Canada, does protect against this serotype.  Notably, serotypes contained within the PC7 vaccine were not a predominant cause of disease in Canada in 2011.

This figure also shows the serotypes which are covered by particular vaccines:

Return to Figure 6

Figure 7. Proportion (%) of PNEU-C-7 serotypes by age group, 2010-2011

Figure 7. Proportion (%) of PNEU-C-7 serotypes by age group, 2010-2011
Year <2 yrs 2 - 4 yrs 5 - 14 yrs 15 - 49 yrs 50 - 64 yrs 65+ yrs All Ages
2010 5.35 3.29 10.74 12.84 8.58 9.72 9.50
2011 1.84 2.80 5.07 9.89 9.14 6.56 7.44

Return to Figure 7

Figure 8. Proportion (%) of PNEU-C-13 serotypes by age group, 2010-2011

Figure 8. Proportion (%) of PNEU-C-13 serotypes by age group, 2010-2011
Year <2 yrs 2 - 4 yrs 5 - 14 yrs 15 - 49 yrs 50 - 64 yrs 65+ yrs All Ages
2010 63.10 69.74 61.16 58.73 52.03 50.36 55.01
2011 42.94 67.83 57.97 53.43 50.36 43.39 49.56

Return to Figure 8

Figure 9. Proportion (%) of PNEU-P-23 serotypes by age group, 2010-2011

Figure 9. Proportion (%) of PNEU-P-23 serotypes by age group, 2010-2011
Year <2 yrs 2 - 4 yrs 5 - 14 yrs 15 - 49 yrs 50 - 64 yrs 65+ yrs All Ages
2010 78.07 78.95 77.69 84.08 78.34 71.35 77.08
2011 65.03 85.31 81.16 83.89 76.34 65.79 74.48

Return to Figure 9